OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Average Recommendation of “Hold” from Analysts

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) have earned an average recommendation of “Hold” from the five brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $6.3333.

OKYO has been the subject of a number of research reports. Piper Sandler initiated coverage on OKYO Pharma in a research report on Friday, February 20th. They issued an “overweight” rating and a $7.00 price objective for the company. B. Riley Financial assumed coverage on OKYO Pharma in a research note on Monday, December 8th. They issued a “buy” rating and a $5.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OKYO Pharma in a research report on Thursday, January 22nd. Finally, HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of OKYO Pharma in a research note on Thursday, January 29th.

OKYO Pharma Stock Down 3.1%

Shares of OKYO opened at $1.57 on Tuesday. The company has a 50-day simple moving average of $1.94 and a 200-day simple moving average of $2.09. OKYO Pharma has a 52 week low of $1.03 and a 52 week high of $3.35.

OKYO Pharma (NASDAQ:OKYO) last released its earnings results on Friday, January 30th. The company reported ($2.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($2.21). On average, research analysts anticipate that OKYO Pharma will post -0.17 earnings per share for the current fiscal year.

Institutional Trading of OKYO Pharma

Several institutional investors have recently made changes to their positions in the business. XTX Topco Ltd acquired a new stake in shares of OKYO Pharma during the 4th quarter valued at about $36,000. Renaissance Technologies LLC raised its position in OKYO Pharma by 235.0% in the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after purchasing an additional 96,800 shares in the last quarter. Finally, Citadel Advisors LLC bought a new position in OKYO Pharma during the third quarter worth about $31,000. 2.97% of the stock is currently owned by institutional investors and hedge funds.

About OKYO Pharma

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.